#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma stage III High-grade B-cell lymphoma Immune-mediated myasthenia gravis Hepatocellular carcinoma Crigler-Najjar syndrome Spina bifida Neuroendocrine cell hyperplasia of infancy Oesophageal atresia Superficial vein thrombosis Cholangitis sclerosing Leiomyosarcoma Metachromatic leukodystrophy Alagille syndrome Acquired haemophilia Alpha-1 antitrypsin deficiency More trials…

    Learn about Rare Diseases

    Basal cell naevus syndrome – Basic Information Short-bowel syndrome – Trials in Disease Hereditary hypophosphataemic rickets – Treatment Usher’s syndrome – Diagnostics Phenylketonuria – Trials in Disease Haemophilia A without inhibitors – Life with Disease Haemophilia B without inhibitors Optic glioma – Diagnostics Propionic acidaemia – Life with Disease Erdheim-Chester disease – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Regtivex Oxacillin Cipaglucosidase Alfa Charcoal, Activated Gs-5718-03 Thiamine Hydrochloride Csm-Gw Efpegerglucagon NALOXEGOL Arbaclofen Naloxegol Oxalate ATIGOTATUG AMMONIUM (15N) CHLORIDE Valproic Acid Casimersen Etranacogene Dezaparvovec Bi 690517 Ofloxacin Hydrochloride Heparin Sodium Eletriptan More therapies…

    Learn about Your Condition

    Peritoneal cancer index Abdominal infection Cardiac failure congestive Epidermolysis bullosa Breast cancer stage II Multiple sclerosis relapse Herpes zoster Uterine leiomyosarcoma Pyoderma gangrenosum Hyperlipidaemia Osteotomy Paget's disease of the vulva Pneumococcal infection Transplantation complication Diabetic ketoacidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study on the Effects of 30% vs. 60% Oxygen Levels at Birth for Improving Development in Premature Infants

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Premature baby
    Investigated Drugs:
    • Oxygen Ph.eur.
    Ireland

  • Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Capivasertib
    • Fulvestrant
    Germany

  • Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Congenital cystic kidney disease
    Investigated Drugs:
    • Tolvaptan
    Belgium Germany Poland Spain

  • Study on the Effectiveness of Infliximab, Ustekinumab, and Vedolizumab for Patients with Resistant Crohn’s Disease

    Recruiting

    2 1 1 1 1
    Investigated Drugs:
    • Infliximab
    • Ustekinumab
    • Vedolizumab
    Poland

  • Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    • Patritumab Deruxtecan
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study on HUVR-CARTemis-1 Therapy for Patients with Relapsed Multiple Myeloma After Allogeneic Transplant Using a Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Autologous Peripheral Blood-Derived Cd4 And Cd8 T Lymphocytes, Transduced With A Lentiviral Vector To Expressing A Chimeric Receptor Against Bcma With Co-Stimulatory Sequences 4-1-Bb And Cd3 Zeta
    • Dexchlorpheniramine
    • Allopurinol
    Spain
Previous Page
1 … 478 479 480 481 482 … 1,653
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!